Sundrug Co.,Ltd.
Sundrug Co.,Ltd. (SDGCF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sdgcf · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Sundrug Co.,Ltd. (SDGCF) measures how much investors pay for each dollar of the company's trailing earnings. SDGCF's current PE ratio of 14.41x is calculated by dividing its stock price of $30.97 by its TTM earnings per share of $268.35. −6.8% discount vs 5Y avg 15.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%22.6x
MedianQ3 · 75%2599.9x
Max
At 14.41x, SDGCF's current P/E is lower than in 0% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Sundrug Co.,Ltd.You SDGCF | $3.6B | 14.41x | -28.6% | $268.35 |
 Ansell Limited ANSLF | $2.8B | 25.74x | +27.5% | $0.70 |
 Bumrungrad Hospital Public Company Limited BUGDF | $3.8B | 18.03x | -10.7% | $9.44 |
 Bumrungrad Hospital Public Company Limited BUHPF | $4.3B | 18.86x | -6.5% | $9.44 |
 MediPal Holdings Corporation MAHLY | $4.0B | 12.80x | -36.6% | $219.14 |
 MediPal Holdings Corporation MEPDF | $3.8B | 14.50x | -28.2% | $207.98 |
 Nihon Kohden Corporation NHNKY | $2.8B | 31.16x | +54.4% | $47.32 |
Industry Average 6 peers with valid PE | — | 20.18x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 16.56x | $270.05 | +3.0% | |
2025-03-31 FY2025 | 16.07x | $262.90 | +8.2% | |
2024-03-31 FY2024 | 14.86x | $249.07 | +0.8% | |
2023-03-31 FY2023 | 14.73x | $219.83 | -2.5% | |
2022-03-31 FY2022 | 15.12x | $204.02 | -20.7% | |
2021-03-31 FY2021 | 19.06x | $216.67 | -99.0% | |
2020-03-31 FY2020 | 1816.24x | $1.88 | +11.4% | |
2019-03-31 FY2019 | 1629.94x | $1.85 | -31.9% | |
2018-03-31 FY2018 | 2392.10x | $2.00 | +8.3% | |
2017-03-31 FY2017 | 2209.30x | $1.77 | -15.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Sundrug Co.,Ltd. (SDGCF) measures how much investors pay for each dollar of the company's trailing earnings. SDGCF's current PE ratio of 14.41x is calculated by dividing its stock price of $30.97 by its TTM earnings per share of $268.35.
Frequently asked questions
SDGCF pe ratio · 6 questionsSDGCF's current PE ratio is 14.41x as of 2026-06-09, based on a stock price of $30.97 and TTM EPS of $268.35. Data sourced from Financial Modeling Prep via SDGCF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sundrug Co.,Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09